Structural & Congenital Heart Disease

The use of transcatheter mitral valve repair (TMVR) systems continues to grow rapidly nearly six years after the FDA approved the U.S.'s first such treatment, according to research published in the American Journal of Cardiology. In contrast, rates of surgical mitral valve repair (SMVR) have remained steady.

Patients with severe aortic regurgitation (AR) may be better off receiving valve operations before symptoms appear that “trigger” guideline recommendations for these surgeries, according to a new study in JACC: Cardiovascular Imaging.

A single-center study with more than a decade of follow-up supports the long-term efficacy of patent foramen ovale (PFO) closure for the prevention of recurrent ischemic events, showing only 1 percent of patients had an ischemic stroke and 2.9 percent experienced a transient ischemic attack.

Chronic kidney disease (CKD), even in its moderate stages, is associated with an increased risk of aortic stenosis, according to research published ahead of print in the Journal of the American College of Cardiology.

A prospective, single-center study from Denmark suggests nearly half of patients develop a new conduction abnormality after transcatheter aortic valve replacement (TAVR), impacting their short-term and long-term prognosis.

Abbott plans to acquire Cephea Valve Technologies, a company developing a transcatheter mitral valve replacement (TMVR) device, the Chicago-area healthcare giant announced Jan. 16.

The University of Florida College of Veterinary Medicine has partnered with veterinary cardiologist Masami Uechi, DVM, PhD, to launch the country’s first open heart surgery program for dogs later this year.

The FDA has approved the Amplatzer Piccolo Occluder as a minimally invasive treatment option for patent ductus arteriosus (PDA) in newborns weighing as little as two pounds. According to its manufacturer, Abbott, it is the first such device in the world to be approved for babies so small.

Patients with atrial fibrillation can safely continue oral anticoagulation (OAC) while undergoing transcatheter aortic valve replacement (TAVR), suggests a retrospective study published Jan. 7 in the American Journal of Cardiology.

Adults with congenital heart disease (CHD) report better health-related quality of life (HRQoL) when treated with surgical or catheter interventions rather than drug therapy or surveillance, according to research published Jan. 8 in the American Journal of Cardiology.

Almost 95 percent of patients survived 25 years after discharge for surgical repair of tetralogy of Fallot without requiring a transplant, according to a U.S. registry study published in JAMA Cardiology. While this statistic highlights the “excellent” outcomes for this congenital heart condition, the report’s authors also identified areas for further improvement.

Developing an effective triage process for patients on the transcatheter aortic valve replacement (TAVR) waitlist could be critical to those patients’ postprocedural outcomes as the intervention continues to gain traction and popularity, researchers reported Jan. 5 in the Journal of the American Heart Association.